JP2023505915A5 - - Google Patents

Info

Publication number
JP2023505915A5
JP2023505915A5 JP2022554968A JP2022554968A JP2023505915A5 JP 2023505915 A5 JP2023505915 A5 JP 2023505915A5 JP 2022554968 A JP2022554968 A JP 2022554968A JP 2022554968 A JP2022554968 A JP 2022554968A JP 2023505915 A5 JP2023505915 A5 JP 2023505915A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
cancer
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022554968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505915A (ja
JP7681616B2 (ja
Filing date
Publication date
Priority claimed from KR1020190149117A external-priority patent/KR20210061202A/ko
Application filed filed Critical
Publication of JP2023505915A publication Critical patent/JP2023505915A/ja
Publication of JP2023505915A5 publication Critical patent/JP2023505915A5/ja
Priority to JP2025079712A priority Critical patent/JP2025120182A/ja
Application granted granted Critical
Publication of JP7681616B2 publication Critical patent/JP7681616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022554968A 2019-11-19 2020-11-19 アデノシン受容体拮抗薬化合物 Active JP7681616B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025079712A JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0149117 2019-11-19
KR1020190149117A KR20210061202A (ko) 2019-11-19 2019-11-19 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
PCT/IB2020/000971 WO2021099838A1 (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025079712A Division JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Publications (3)

Publication Number Publication Date
JP2023505915A JP2023505915A (ja) 2023-02-13
JP2023505915A5 true JP2023505915A5 (https=) 2024-12-04
JP7681616B2 JP7681616B2 (ja) 2025-05-22

Family

ID=75980093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554968A Active JP7681616B2 (ja) 2019-11-19 2020-11-19 アデノシン受容体拮抗薬化合物
JP2025079712A Pending JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025079712A Pending JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Country Status (14)

Country Link
US (1) US12606564B2 (https=)
EP (1) EP4061817A4 (https=)
JP (2) JP7681616B2 (https=)
KR (3) KR20210061202A (https=)
CN (2) CN116425756B (https=)
AU (2) AU2020386189B2 (https=)
BR (2) BR122023020015A2 (https=)
CA (1) CA3158731A1 (https=)
CL (1) CL2022001307A1 (https=)
IL (1) IL293107A (https=)
MX (1) MX2022005976A (https=)
PH (1) PH12022551223A1 (https=)
TW (3) TWI850492B (https=)
WO (3) WO2021099832A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TW202508599A (zh) * 2023-05-19 2025-03-01 南韓商尹諾衛醫藥有限公司 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025170158A1 (ko) * 2024-02-08 2025-08-14 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507552A (ja) * 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US20060128956A1 (en) * 2003-04-21 2006-06-15 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011050160A1 (en) 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
JP7337502B2 (ja) 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
DE102017125533A1 (de) 2017-10-31 2019-05-02 Helmholtz-Zentrum Dresden - Rossendorf E.V. 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP4368184A3 (en) 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
AU2020389474B2 (en) 2019-11-19 2026-03-12 Clariant International Ltd Solvates of abscisic acid and liquid compositions containing abscisic acid
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Similar Documents

Publication Publication Date Title
JP2023505915A5 (https=)
EP4161511B1 (en) Novel small molecules for targeted degradation of untargetable kras in cancer therapy
JP7224334B2 (ja) 大環式化合物およびその使用
JP6285950B2 (ja) グルタミナーゼの複素環式阻害剤を用いるがんの処置
CN101678029B (zh) 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
JP2025120182A5 (https=)
JP2022514352A5 (https=)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2017044858A3 (en) Inhibitors of cyclin-dependent kinases
HK1254469A1 (zh) 稠合双环嘧啶衍生物及其用途
HU229076B1 (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
CA2840986A1 (en) Treating cancer with hsp90 inhibitory compounds
JP2010539095A5 (https=)
JP2014527082A5 (https=)
CN112585136A (zh) 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
JP2022516555A5 (https=)
JP2021502423A5 (https=)
JP2020531414A5 (https=)
WO2019195443A1 (en) Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
JP2023509359A5 (https=)
JP2024125139A5 (https=)
BR112021022966A2 (pt) Método para reduzir o tamanho do tumor
TW200744603A (en) Novel anticancer concomitant drug
AU2016296997B2 (en) Chlorobenzene substituted azaaryl compounds